Travere therapeutics CEO Eric Dube sells $25.4m in shares

Travere Therapeutics CEO Eric Dube sold $25.4 million worth of company shares over a three-day period in September 2026, exercising employee stock options and subsequently selling all 400,000 shares at prices ranging from $61.99 to $65.31. The stock had surged 168% over the previous year, leading to speculation that the sales were made in anticipation of the stock's overvaluation.

Meanwhile, Travere Therapeutics reported robust financial results for Q2 2026, with revenue reaching $169.6 million, driven by a 96% increase in FILSPARI sales to $141.1 million. The company's confidence in the early uptake of its newly launched drug for FSGS and the positive progress of payer access further indicate a period of significant growth for the company.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.